The list includes molecular targets for which there is evidence that indicates that they are not associated with the growth or progression of pediatric tumors, and for which requirement for early pediatric assessment of drugs and biologics directed at these targets could be waived.
The Non-Relevant Molecular Target Leading to Waiver List
For more information, please visit FDA’s Oncology Center of Excellence.